IBRX ImmunityBio, Inc. Insider Trading

Director Cheryl Cohen sold 131,210 shares (131.2K) of IBRX at $9.50 on 2026-07-02 via scheduled 10b5-1 plan; retains 125,386 non-derivative shares plus 111,958 stock options.

Director Cheryl Cohen executed a scheduled sale of 131,210 shares at $9.50, reducing her non-derivative holdings by 51.1% to 125,386 shares. The transaction was part of a pre-arranged 10b5-1 trading plan and therefore represents a scheduled divestment rather than a discretionary decision. While the stock has climbed 28.8% over the prior 30 days and 29.9% over the prior 90 days from the sale date, the underlying company reported a net loss of $632.8M in its most recent full fiscal year, despite posting strong annual revenue growth of 668.3%. Cohen retains meaningful exposure through 111,958 stock options, indicating continued economic alignment with the company even after the partial share reduction.

Director Christobel Selecky sells 159.5K shares of IBRX at $9.02 per share under pre-arranged 10b5-1 plan

Christobel Selecky, a director, sold 159,478 shares of ImmunityBio (IBRX) at $9.02 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, generating $1,439,065.68 in proceeds. This transaction is scheduled rather than discretionary, eliminating timing as an interpretive factor. ImmunityBio reported a net income of $-632,782,000.00 in its most recent full fiscal year while generating quarterly revenue of $44,206,000.00, indicating significant near-term losses despite +668.3% annual revenue growth. The stock is currently trading at $8.91, approximately -28.3% from its 52-week high of $12.43 and 30-day return of +28.8%, reflecting recent upside recovery from depressed levels.

Director Simon Barry J. sells 175,000 IBRX shares in 2 transactions for $1,783,601.50, reducing stake 5.6% while stock near 52-week high.

Simon Barry J., Director of ImmunityBio, executed two separate sales totaling 175,000 shares for $1,783,601.50 over three trading days at prices ranging from $9.25 to $10.25, with a blended average price of $10.19. This sale reduced his holdings from 3,100,821 shares to 2,925,821 shares, a reduction of 5.6%. The timing of these sales coincides with a period of significant price momentum: the stock has appreciated 79.1% over the prior 30 days and 442.2% over the prior 90 days, and now trades at $11.55, matching its 52-week high. His prior two sales at IBRX (both on 2026-01-20) had 30-day returns of +31.6% and +9.3%, indicating the stock continued rising after those transactions. The company operates with substantial losses ($-67,253,000 net income on quarterly revenue of $32,061,000), though it reported 668.3% annual revenue growth. The confluence of strong price appreciation, the director's decision to sell a material quantity of shares at prices below the current market level, and the company's unprofitable operational posture merit attention to whether this reflects conviction about valuation levels or execution against a pre-planned schedule.

Director Simon Barry J. sold 151,967 shares ($1.1M) in 2 transactions at ImmunityBio (IBRX) on 2026-01-20 as stock hits 52-week high of $6.92

Simon Barry J. executed 2 separate sales totaling 151,967 shares for $1,094,296.68 at a blended average price of $7.20, reducing his holdings from 3,243,571 shares to 3,091,604 shares (a 4.7% reduction). The timing coincides with the stock reaching its 52-week high of $6.92 and after substantial recent momentum: the stock has climbed 204.8% over the past 30 days and 189.5% over the past 90 days. Notably, this activity occurs in a company with significant cash burn—annual net income stands at negative $67,253,000—despite impressive top-line growth of 2270.6% year-over-year. The sale at elevated valuations relative to the 52-week trading range raises questions about asset allocation decisions at a point of peak momentum.